clofibric acid has been researched along with Lipodystrophy, Familial Partial in 1 studies
Clofibric Acid: An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.
clofibric acid : A monocarboxylic acid that is isobutyric acid substituted at position 2 by a p-chlorophenoxy group. It is a metabolite of the drug clofibrate.
Lipodystrophy, Familial Partial: Inherited conditions characterized by the partial loss of ADIPOSE TISSUE, either confined to the extremities with normal or increased fat deposits on the face, neck and trunk (type 1), or confined to the loss of SUBCUTANEOUS FAT from the limbs and trunk (type 2). Type 3 is associated with mutation in the gene encoding PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sleilati, GG | 1 |
| Leff, T | 1 |
| Bonnett, JW | 1 |
| Hegele, RA | 1 |
1 other study available for clofibric acid and Lipodystrophy, Familial Partial
| Article | Year |
|---|---|
Efficacy and safety of pioglitazone in treatment of a patient with an atypical partial lipodystrophy syndrome.
Topics: Adult; Clofibric Acid; Female; Humans; Hypoglycemic Agents; Insulin; Lipodystrophy, Familial Partial | 2007 |